Skip to Main Content
Table 1—

HRs for ESRD

LDL cholesterol at year 1Combined
Losartan
Placebo
nHR (95% CI)nHR (95% CI)nHR (95% CI)
Adjusted by        
    Baselinea Increase 409 1.00 180 0.70 (0.44–1.11) 229 1.00 
 Decrease 652 0.71 (0.53–0.96)* 360 0.50 (0.34–0.75)* 292 0.76 (0.52–1.13) 
    Baseline + year 1b Increase 409 1.00 180 0.88 (0.55–1.39) 229 1.00 
 Decrease 652 1.11 (0.81–1.53) 360 0.93 (0.61–1.41) 292 1.18 (0.79–1.76) 
LDL cholesterol at year 1Combined
Losartan
Placebo
nHR (95% CI)nHR (95% CI)nHR (95% CI)
Adjusted by        
    Baselinea Increase 409 1.00 180 0.70 (0.44–1.11) 229 1.00 
 Decrease 652 0.71 (0.53–0.96)* 360 0.50 (0.34–0.75)* 292 0.76 (0.52–1.13) 
    Baseline + year 1b Increase 409 1.00 180 0.88 (0.55–1.39) 229 1.00 
 Decrease 652 1.11 (0.81–1.53) 360 0.93 (0.61–1.41) 292 1.18 (0.79–1.76) 
*

P < 0.05.

a

Adjusted by baseline albuminuria (log transformed), serum creatinine, serum albumin, hemoglobin, and LDL cholesterol.

b

Adjusted by the above and albuminuria at year 1.

Close Modal

or Create an Account

Close Modal
Close Modal